Kathrine Lederballe Grøn

A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry

Bente Glintborg, Inge Juul Sørensen, Anne Gitte Loft et al. · Annals of the Rheumatic Diseases · 2017 · 245 citations

Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial

Merete Lund Hetland, Espen A. Haavardsholm, Anna Rudin et al. · BMJ · 2020 · 108 citations · Full text

The association of fatigue, comorbidity burden, disease activity, disability and gross domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in the Quest-RA program.

Kathrine Lederballe Grøn, Lykke Midtbøll Ørnbjerg, Merete Lund Hetland et al. · PubMed · 2015 · 74 citations · Full text

Risk of serious infections in patients with rheumatoid arthritis treated in routine care with abatacept, rituximab and tocilizumab in Denmark and Sweden

Kathrine Lederballe Grøn, Elizabeth V. Arkema, Bente Glintborg et al. · Annals of the Rheumatic Diseases · 2019 · 65 citations

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial

Mikkel Østergaard, Ronald van Vollenhoven, Anna Rudin et al. · Annals of the Rheumatic Diseases · 2023 · 44 citations · Full text